This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Introducing the new Deputy Editor of Pharmacology Research & Perspectives (PR&P)

Published: 21 Aug 2020 in Journal news

The British Pharmacological Society (BPS) is pleased to announce the appointment Professor Jennifer Martin as the new Deputy Editor of Pharmacology Research & Perspectives (PR&P), the open-access journal co-owned by the Britsh Pharmacological Society, the American Society for Pharmacology and Experimental Therapeutics (ASPET) and Wiley.

Professor Martin is a senior physician in internal medicine and the Chair of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle, Australia and runs a large clinical pharmacology drug development and repurposing program. She is a Director of Pathway of Research to Evaluation of Dose-Individualised Cancer Therapy (PREDICT), Director of the Australia Centre for Cannabinoid Clinical and Research Excellence (ACRE), a Board Director of the Royal Australasian College of Physicians and an elected member of the New South Wales Council at the Australian Institute of Company Directors. Over the last 12 years she has been a member of the executive editorial teams of the British Journal of Clinical Pharmacology, the Medical Journal of Australia and the Internal Medicine Journal.



Professor Andrew J Lawrence, Editor-in-Chief of PR&P, says: “I am delighted with the appointment of Professor Jennifer Martin as the incoming Deputy Editor of PR&P. The end of my tenure will see Dr Mike Jarvis take the helm as Editor-in-Chief and Jenny become his partner in crime! Given our high clinical content within the journal, Jenny will bring valuable experience and expertise to PR&P. I am certain that PR&P is in good hands going forwards.”

Professor Martin says: “I am very excited about the opportunity to work with PR&P’s global editorial team, with expertise spanning drug discovery to clinical medicine use, focusing on innovative pharmacological targets and drug delivery to patients. We will bring new science to pharmacology, and new pharmacology to patients. Quality drug development and individualized drug therapy will be important research areas going forward, and the publication of emerging pharmacological methods, particularly artificial intelligence and knowledge around the interface of human physiology and pharmacology to target variability in drug response, are opportunities to improve patient health.”

Professor Martin will begin the role in January 2021.